Compare GSK plc (GSK) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Boston Beer Company Inc — how do they compare? GSK plc trades at $52.74 (market cap $101.34B), while Boston Beer Company Inc trades at $179.22 (market cap $1.77B). The key difference: GSK plc is far larger — about 57.3× Boston Beer Company Inc's market cap, and GSK plc pays a 3.49% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| GSK | SAM | |
|---|---|---|
Market Cap | $101.34B | $1.77B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $260.05 |
52-Week Low | $36.20 | $161.08 |
Enterprise Value | $121.95B | $1.64B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SAM trades at $179.3, up 6.25% over 24 hours, with a bearish technical signal but oversold short-term RSI. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. The company maintains strong operating cash flow of $270.16M in 2025, though net income margin turned negative in 2026. Analyst consensus is a hold-heavy stance with a $213.50 price target, indicating cautious optimism amid brand investments and volume pressures.
Outlook is mixed; growth drivers include innovation in Beyond Beer and cost initiatives, but risks from volume declines and competitive pressure persist. The stock offers potential upside to the consensus target, yet investors face headwinds from profitability challenges and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
